Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-5000 in Stage II-III Triple-Negative Breast Cancer (VITAL-TNBC)
NCT07652242Phase 1Recruiting
- Sponsor
- Immunomic Therapeutics, Inc.
- Start
- Jul 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of ITI-5000 in triple-negative breast cancer (TNBC) (5 arms), sponsored by Immunomic Therapeutics, Inc. Primary endpoint: Dose-Limiting Toxicities. Started Jul 2026; status: recruiting.
02
Drugs
ITI-5000
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07652242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652242.